Treatment | Number (percentage) of patients |
---|---|
csDMARDs/biologics started at baseline, n (%) | 152 (91.0) |
 - MTX, n (%) | 147 (88.0) |
 - Other csDMARDs, n (%) | 4 (2.4) |
 - csDMARD triple therapy, n (%) | 1 (0.6) |
Anti-TNF at baseline, n (%) | 1 (0.6) |
Anti-TNF ever, n (%) | 18 (10.8) |
Other bDMARDs | 6 (3.6) |
Oral glucocorticoids, n (%) | 138 (82.6) |
Calcium supplements, n (%)a | 79 (49.1) |
Bisphosphonates, n (%)b | 7 (6.0) |